NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
Myeloma Canada: Patient Handbook - Myeloma and the Kidney
International Myeloma Working Group Recs for Diagnosis & Manag. of Myeloma-Related Renal Impairment
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Myeloma UK - Myeloma Animations Series: Proteasome inhibitors in myeloma
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
Myeloma UK - Myeloma Animations Series: Immunotherapy in myeloma
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
Myeloma UK - Myeloma Animations Series: Genetic causes of myeloma
Nature Videos: Tumour immunology and immunotherapy